Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

Inclusion Criteria: * Histologically or cytologically confirmed metastatic colorectal cancer (adenocarcinoma) * At least one measurable lesion (RECIST criteria) * Life expectancy ≥ 3 months * ECOG performance status 0-2 * Adequate hematologic function: ANC ≥ 1.5×109 /L，Hb ≥ 90 g/L，PLT ≥ 100×109 /L * Adequate renal function: Cr ≤ 1.25×ULN or Creatinine clearance ≥ 60 ml/min * Adequate hepatic function: BIL ≤ 1.5×ULN, ALT/AST ≤ 2.5×ULN, Alkaline phosphatase ≤ 5×ULN * Patients have not previously received palliative chemotherapy, immunological/ biological treatment * No adjuvant chemotherapy in last six months * Target lesion has not received local radiotherapy * Written informed consent Exclusion Criteria: * Diagnosis of colorectal neuroendocrine tumor, undifferentiated carcinoma, adenosquamous carcinoma, squamous cell carcinoma * Evidence of serious or uncontrolled infection * Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension) * Pregnant or lactating women * Women of childbearing potential refused to practice acceptable methods of birth control to prevent pregnancy * Allergic to any of the study drug * Intestinal obstruction, intestinal perforation, or stroke within 3 months * Participation in other clinical studies